Breaking News Cannabinoids Cannabis Buzz CannabisExtraction CannabisOil CapitalInvestment Distillation EBITDA financialresults FSE Latest Market News Medical Use MediPharmLabs OTCQX revenue strategy The Market Buzz TSX

Breaking News: MediPharm Labs Announces Q1 2019 Revenue of $ 22 Million and Adjusted EBITDA of $ 4.3 Million

MediPharm Labs Corp. (TSX-V: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or “Company”) a worldwide leader in specialized research-driven hashish extraction, distillation, purification

and cannabinoid isolation, is a pledge to announce the top of the month. Key Q1 2019 Financial and Yr-to-Date Highlights

  • Revenue of $ 22 million, the 115% improve over This fall 2018, Gross Revenue of $ 6.9 million, Gross Margin 31%
  • ] Adjusted EBITDA (1) of $ 4.3 million, a 102% improve over This fall 2018, Adjusted EBITDA (1) margin of 20%
  • Robust, constructive cashflows from operations
  • Q1 revenue consists of $ 7.6 million personal label hashish oil contract with a large Licensed Producer
  • Acquired greater than 5,000 kg (or 5 million grams) of dried cannabis in the last two weeks
  • Continued vital capital investment, further growing
  • Acquired over $ 7 million in cash proceeds from warrant workouts on to March 31, 2019 [19659011] "As a differentiated cannabis company, we achieved strong position in the field of canadian cannabis companies," stated Patrick McCutcheon, Chief Government Officer, MediPharm Labs. Our revenue and adjusted EBITDA performance, which is more than doubled to $ 22 million cannabinoid-based by-product Formulations at scale. That is additionally an indication of our capacity to realize a constructive return on investment. ”

    , with TerrAscend Corp., and finishing two new personal label supply agreements in the quarter, this robust gross sales momentum continued nicely into the second quarter, "

    " In anticipation of the fall of 2019 vapeables, edibles and topicals as we anticipate our market.

    Key Operational and Yr-to-End -Date 2019 Highlights

    • Executed a number of personal label sales alternatives
    • Signed first international personal label sale agreement with AusCann Group Holdings Ltd. for the export of cannabis oil from Canada [Australia]
    • Continued enlargement of white label options platform for lively components; , edibles, Drinks and topicals;
    • Appointed Famend Medical Professional and Pharmaceutical Researcher
    • Appointed Braden Fenske, former Group Product Director, International Strategic Advertising for Biosense Webster Inc. , Johnson & Johnson Company, newly created Chief Technique Officer position on advance corporate strategy, international progress and strategic partnerships
    • Assembled numerous workforce of globally famend specialists to type our Science Advisory Committee

    Near Time period Catalysts

    1. New agreements in process
    2. Giant volume purchases of dried hashish
    3. Canadian legalization of vapeables and edibles in fall 2019
    4. First oil cargo to AusCann Group Holdings in Australia from Canadian extraction-only comp any
    5. Advancing worldwide progress technique – vital progress on development of MediPharm Labs
    6. Continued progress in the direction of European Union GMP
    7. First Financial Quarter 2019 Key Monetary Measures

      Three-months ended March 31, 2019
      $ '000s December 31, 2018
      $' 000s Revenue 21,950 10,198 Gross revenue 6,862 3,967 Gross margin % 31% 39% Internet loss (573) (three,542) Adjusted EBITDA (1) four,310 2,129 Adjusted EBITDA margin % 20% 21% [19659033] [19659055] Ong OTC Strategic Initiatives

      1. Forge Further Home and Worldwide Sales and Provide Businesses: Utilizing a First-Mover and Proprietary Benefits
      2. Increase White-Label Options Platform Together with Formulation, Processing and Distribution Providers: Anticipated legalization of vapeables, Beverages and topicals in October 2019 in addition to a non-cannabis firm, we are wanting ahead to increasing our vary of merchandise to corporations in america. processing and distribution.
      3. Improve cGMP-built Manufacturing Capacity: The Firm is a monitor document of 250,000 kg over a complete of 7 extraction strains. Utilizing CGMP Methods for Multiple Exposure.
        Flexibility over a number of extraction strains within the hashish market.
      4. Achieve European Union GMP Certification at the Barrie Facility: Anticipate to realize a serious European demand.
      5. Complete First Worldwide Facility in Australia: Australian Middle of Excellence is predicted to be commissioned in H2-2019, pending Licensing, and will act as a hub to access Asia-Pacific regions. 75,000 kg of dried cannabis. The Australian area is predicted to have a low-cost supply input for manufacturing.
      6. Broaden Secondary Extraction Capabilities: Advancing Industrial-scale Distillation and Business Chromatography. Improvement is underway for specialized, proprietary chromatography processing with Trials expected to begin H2 2019.
      7. First Quarter 2019 Financial Results Summary

      First Quarter 2019 Monetary Results Abstract

      M&A and Joint Venture Alternatives: The Company has a strong pipeline of opportunities to duplicate its unique enterprise mannequin in other jurisdictions. Three-month period ended March 31 2019 2018 $ '000s $' 000s Revenue from contracts with clients (15,088 ) – Gross revenue 6,862 – Common administrative bills ( Advertising and promoting expenses (907 ) (11 ) Share-based compensation expense (3,972 ) (758 ) Different operating bills (7 ) [1] 9659078] (105 ) Working loss (1,268 ) Finance revenue 5 – Finance expense 19659078] (198 ) Loss before taxation (325 ) Taxation expense (248 ) – Internet loss for the interval (573 ) (1,349 )

      (1) Adjusted EBITDA shouldn’t be a acknowledged performance measure beneath IFRS. Adjusted EBITDA is included in the Supplementary Disclosure Assertion for Administration and Non-Money Remuneration. Adjusted EBITDA is defined as internet loss, curiosity, and share-based compensation. Adjusted EBITDA has limitations as an Analytical device because it does not embrace depreciation and amortization expense. Because of these limitations, the adjusted EBITDA shouldn’t be thought-about as a benchmark for the Company's outcomes as reported beneath IFRS. EBITDA calculated in accordance with IFRS is operating revenue. Working loss to Adjusted EBITDA.

      About MediPharm Labs Corp.

      Based in 2015, MediPharm Labs has the Distinction of being the first firm in Canada to turn into a licensed producer for cannabis oil manufacturing. This product is a manufacturer and producer of cGMP (present Good Manufacturing Practices). MediPharm Labs has been invested in an professional, research-driven staff, state-of-the-art know-how, downstream extraction methodologies and purpose-based delivery providers. MediPharm Labs' personal label program is a excessive margin enterprise for the company, where it can be used as a foundation for a personal label.

      By means of its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has additionally been used in the subject of drugs and hashish merchandise in Australia.